oleclumab,durvalumab
astrazeneca
['biomarker', 'synergy', 'breast', 'tnbc']
from the lab to the synergy investigator-initiated trial sponsored by and now back to the lab to shed light on mechanisms associated with responses and identify predictive biomarkers to chemo-immunotherapy in advanced #tnbc #breastcancer #esmo2022 
Medical Oncologist, MD PhD I #BreastCancer immunotherapy investigator and scientist @JulesBordet Lecturer @ULBruxelles